AKT1 and liver cancer: Administering ginsenoside Rg3 and sorafenib together markedly reduces the survival, glucose uptake, and lactate concentrations in liver cancer (Hep G2 and BEL7404) cells, a process linked to the glycolysis mediated by HK2 and the PI3K/AKT signaling pathway [676].